Gefitinib

Among patients with non-small cell lung cancer, mutation of Epidermal Growth Factor Receptor (EGFR) is seen in about 20% of Caucasian patients.

This altered receptor produces continuous stimulation through different pathways to provide stimulus for cancer cells to survive, proliferate and metastasize. Inhibition of this receptor and the resultant signalling cascade is possible through Gefitinib which is a Tyrosine Kinase Inhibitor (TKI).

A detailed discussion is usually held by the treating physician to explain this treatment to the patients. The medical information sheets on such treatments given to these patients provide useful information about the name and the side effects but do not provide the rationale, mechanism of action and the benefit of these treatments over a long interval of time.

This App is designed to bridge this gap of information; in the pictorial format (a picture is better than thousand words). In addition, the App aims to keep this education session individualized and simple to understand.